{
  "disease_name": "Mucopolysaccharidosis type 2",
  "orpha_code": "580",
  "drugs": [
    {
      "name": "ELAPRASE",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/131369?name=580&mode=orpha&region=",
      "regulatory_id": "131369",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "ELAPRASE(Tradename                        - 08/01/2007)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "ELAPRASE(Tradename                        - 08/01/2007)",
        "(Tradename                        - 08/01/2007)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/75869?name=580&mode=orpha&region=&status=all",
          "text": "ELAPRASE",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131369?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Idursulfase beta",
      "substance_url": "/en/drug/substance/627620?name=580&mode=orpha&region=&status=all",
      "substance_id": "627620",
      "regulatory_url": "/en/drug/regulatory/627621?name=580&mode=orpha&region=",
      "regulatory_id": "627621",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Idursulfase beta(Medicinal product                        - 15/10/2021)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Idursulfase beta(Medicinal product                        - 15/10/2021)",
        "(Medicinal product                        - 15/10/2021)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/627620?name=580&mode=orpha&region=&status=all",
          "text": "Idursulfase beta",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/627621?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human iduronate 2-sulfatase gene",
      "substance_url": "/en/drug/substance/627878?name=580&mode=orpha&region=&status=all",
      "substance_id": "627878",
      "regulatory_url": "/en/drug/regulatory/627881?name=580&mode=orpha&region=",
      "regulatory_id": "627881",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human iduronate 2-sulfatase gene(Medicinal product                        - 20/08/2021)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human iduronate 2-sulfatase gene(Medicinal product                        - 20/08/2021)",
        "(Medicinal product                        - 20/08/2021)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/627878?name=580&mode=orpha&region=&status=all",
          "text": "Autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human iduronate 2-sulfatase gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/627881?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase",
      "substance_url": "/en/drug/substance/558944?name=580&mode=orpha&region=&status=all",
      "substance_id": "558944",
      "regulatory_url": "/en/drug/regulatory/558948?name=580&mode=orpha&region=",
      "regulatory_id": "558948",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase(Medicinal product                        - 26/02/2019)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase(Medicinal product                        - 26/02/2019)",
        "(Medicinal product                        - 26/02/2019)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/558944?name=580&mode=orpha&region=&status=all",
          "text": "Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/558948?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene",
      "substance_url": "/en/drug/substance/446352?name=580&mode=orpha&region=&status=all",
      "substance_id": "446352",
      "regulatory_url": "/en/drug/regulatory/500508?name=580&mode=orpha&region=",
      "regulatory_id": "500508",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene(Medicinal product                        - 08/11/2017)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene(Medicinal product                        - 08/11/2017)",
        "(Medicinal product                        - 08/11/2017)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/446352?name=580&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/500508?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase",
      "substance_url": "/en/drug/substance/628332?name=580&mode=orpha&region=&status=all",
      "substance_id": "628332",
      "regulatory_url": "/en/drug/regulatory/628334?name=580&mode=orpha&region=",
      "regulatory_id": "628334",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase(Medicinal product                        - 16/03/2022)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase(Medicinal product                        - 16/03/2022)",
        "(Medicinal product                        - 16/03/2022)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/628332?name=580&mode=orpha&region=&status=all",
          "text": "Adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/628334?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Idursulfase",
      "substance_url": "/en/drug/substance/70916?name=580&mode=orpha&region=&status=all",
      "substance_id": "70916",
      "regulatory_url": "/en/drug/regulatory/604974?name=580&mode=orpha&region=",
      "regulatory_id": "604974",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Idursulfase(Medicinal product                        - 06/01/2021)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Idursulfase(Medicinal product                        - 06/01/2021)",
        "(Medicinal product                        - 06/01/2021)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/70916?name=580&mode=orpha&region=&status=all",
          "text": "Idursulfase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/604974?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene",
      "substance_url": "/en/drug/substance/510774?name=580&mode=orpha&region=&status=all",
      "substance_id": "510774",
      "regulatory_url": "/en/drug/regulatory/510775?name=580&mode=orpha&region=",
      "regulatory_id": "510775",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene(Medicinal product                        - 17/01/2018)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene(Medicinal product                        - 17/01/2018)",
        "(Medicinal product                        - 17/01/2018)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/510774?name=580&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/510775?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene",
      "substance_url": "/en/drug/substance/446352?name=580&mode=orpha&region=&status=all",
      "substance_id": "446352",
      "regulatory_url": "/en/drug/regulatory/446353?name=580&mode=orpha&region=",
      "regulatory_id": "446353",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene(Medicinal product                        - 10/08/2015)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene(Medicinal product                        - 10/08/2015)",
        "(Medicinal product                        - 10/08/2015)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/446352?name=580&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/446353?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase (HIRMAb-IDS)",
      "substance_url": "/en/drug/substance/365255?name=580&mode=orpha&region=&status=all",
      "substance_id": "365255",
      "regulatory_url": "/en/drug/regulatory/377614?name=580&mode=orpha&region=",
      "regulatory_id": "377614",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase (HIRMAb-IDS)(Medicinal product                        - 13/11/2013)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase (HIRMAb-IDS)(Medicinal product                        - 13/11/2013)",
        "(Medicinal product                        - 13/11/2013)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/365255?name=580&mode=orpha&region=&status=all",
          "text": "Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase (HIRMAb-IDS)",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/377614?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Idursulfase",
      "substance_url": "/en/drug/substance/70916?name=580&mode=orpha&region=&status=all",
      "substance_id": "70916",
      "regulatory_url": "/en/drug/regulatory/133759?name=580&mode=orpha&region=",
      "regulatory_id": "133759",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Idursulfase(Medicinal product                        - 11/12/2001)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Idursulfase(Medicinal product                        - 11/12/2001)",
        "(Medicinal product                        - 11/12/2001)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/70916?name=580&mode=orpha&region=&status=all",
          "text": "Idursulfase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/133759?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "ELAPRASE",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/131158?name=580&mode=orpha&region=",
      "regulatory_id": "131158",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "ELAPRASE(Tradename                        - 24/07/2006)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "ELAPRASE(Tradename                        - 24/07/2006)",
        "(Tradename                        - 24/07/2006)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/75869?name=580&mode=orpha&region=&status=all",
          "text": "ELAPRASE",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131158?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated virus vector expressing human iduronate-2-sulfatase",
      "substance_url": "/en/drug/substance/644779?name=580&mode=orpha&region=&status=all",
      "substance_id": "644779",
      "regulatory_url": "/en/drug/regulatory/644791?name=580&mode=orpha&region=",
      "regulatory_id": "644791",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Adeno-associated virus vector expressing human iduronate-2-sulfatase(Medicinal product                        - 28/03/2023)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Adeno-associated virus vector expressing human iduronate-2-sulfatase(Medicinal product                        - 28/03/2023)",
        "(Medicinal product                        - 28/03/2023)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/644779?name=580&mode=orpha&region=&status=all",
          "text": "Adeno-associated virus vector expressing human iduronate-2-sulfatase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/644791?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS)",
      "substance_url": "/en/drug/substance/637364?name=580&mode=orpha&region=&status=all",
      "substance_id": "637364",
      "regulatory_url": "/en/drug/regulatory/637365?name=580&mode=orpha&region=",
      "regulatory_id": "637365",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS)(Medicinal product                        - 14/07/2022)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS)(Medicinal product                        - 14/07/2022)",
        "(Medicinal product                        - 14/07/2022)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/637364?name=580&mode=orpha&region=&status=all",
          "text": "Recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS)",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/637365?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Idursulfase",
      "substance_url": "/en/drug/substance/70916?name=580&mode=orpha&region=&status=all",
      "substance_id": "70916",
      "regulatory_url": "/en/drug/regulatory/132005?name=580&mode=orpha&region=",
      "regulatory_id": "132005",
      "orpha_substance_code": "ORPHA:580",
      "details": [
        "Idursulfase(Medicinal product                        - 28/11/2001)Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "Idursulfase(Medicinal product                        - 28/11/2001)",
        "(Medicinal product                        - 28/11/2001)",
        "Disease(s) concernedORPHA:580 Mucopolysaccharidosis type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/70916?name=580&mode=orpha&region=&status=all",
          "text": "Idursulfase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/580",
          "text": "ORPHA:580 Mucopolysaccharidosis type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/132005?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "PLERIXAFOR ACCORD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/642317?name=580&mode=orpha&region=",
      "regulatory_id": "642317",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
        "(Tradename                        - 16/12/2022)",
        "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/642316?name=580&mode=orpha&region=&status=all",
          "text": "PLERIXAFOR ACCORD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/29073",
          "text": "ORPHA:29073 Multiple myeloma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/223735",
          "text": "ORPHA:223735 Lymphoma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/642317?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Thiotepa Riemser",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/610636?name=580&mode=orpha&region=",
      "regulatory_id": "610636",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Thiotepa Riemser(Tradename                        - 26/03/2021)",
        "(Tradename                        - 26/03/2021)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/610616?name=580&mode=orpha&region=&status=all",
          "text": "Thiotepa Riemser",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/610636?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "motixafortide",
      "substance_url": "/en/drug/substance/588874?name=580&mode=orpha&region=&status=all",
      "substance_id": "588874",
      "regulatory_url": "/en/drug/regulatory/661036?name=580&mode=orpha&region=",
      "regulatory_id": "661036",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "motixafortide(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "motixafortide(Medicinal product                        - 12/01/2024)",
        "(Medicinal product                        - 12/01/2024)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588874?name=580&mode=orpha&region=&status=all",
          "text": "motixafortide",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/661036?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
      "substance_url": "/en/drug/substance/589233?name=580&mode=orpha&region=&status=all",
      "substance_id": "589233",
      "regulatory_url": "/en/drug/regulatory/589234?name=580&mode=orpha&region=",
      "regulatory_id": "589234",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)",
        "(Medicinal product                        - 20/04/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589233?name=580&mode=orpha&region=&status=all",
          "text": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589234?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
      "substance_url": "/en/drug/substance/589056?name=580&mode=orpha&region=&status=all",
      "substance_id": "589056",
      "regulatory_url": "/en/drug/regulatory/589057?name=580&mode=orpha&region=",
      "regulatory_id": "589057",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)",
        "(Medicinal product                        - 24/03/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589056?name=580&mode=orpha&region=&status=all",
          "text": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589057?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=580&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=580&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=580&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=580&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641081?name=580&mode=orpha&region=",
      "regulatory_id": "641081",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=580&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641081?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=580&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641075?name=580&mode=orpha&region=",
      "regulatory_id": "641075",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=580&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641075?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=580&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=580&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=580&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=580&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=580&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=580&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=580&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T05:59:51.853852",
  "run_number": 1,
  "total_drugs_found": 25,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Mucopolysaccharidosis+type+2&orphaCode=580&name=580&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Mucopolysaccharidosis type 2",
    "orphaCode": "580",
    "name": "580",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}